{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:41Z","timestamp":1772165681572,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12432-x","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T06:38:48Z","timestamp":1768199928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic blood-borne viral hepatitis in a tertiary hospital in Al-Baha, Saudi Arabia: epidemiology, liver enzyme correlations, and treatment outcomes"],"prefix":"10.1186","volume":"26","author":[{"given":"Talal A.","family":"Sallam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabei M.","family":"El-Badry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turki H.","family":"Alkully","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan H.","family":"Alfahemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad A.","family":"Halwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled I.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manal A.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"12432_CR1","unstructured":"World Health Organization. WHO sounds alarm on viral hepatitis infections claiming 3500 lives each day [Internet]. [cited 2025 Aug 20]. Available from: https:\/\/www.who.int\/news\/item\/09-04-2024-who-sounds-alarm-on-viral-hepatitis-infections-claiming-3500-lives-each-day"},{"issue":"4","key":"12432_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.bpg.2012.09.012","volume":"26","author":"G Papatheodoridis","year":"2012","unstructured":"Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Pract Res Clin Gastroenterol. 2012;26(4):371\u201380.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"12432_CR3","unstructured":"World Health Organization. Hepatitis C [Internet]. [cited 2025 Aug 20]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c"},{"issue":"3","key":"12432_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0163-4453(99)90245-1","volume":"38","author":"FZ Al-Faleh","year":"1999","unstructured":"Al-Faleh FZ, Al-Jeffri M, Ramia S, Al-Rashed R, Arif M, Rezeig M, et al. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme. J Infect. 1999;38(3):167\u201370.","journal-title":"J Infect"},{"issue":"2","key":"12432_CR5","first-page":"41","volume":"20","author":"S Mohammed Abdullah","year":"2013","unstructured":"Mohammed Abdullah S. Prevalence of hepatitis B and C in donated blood from the Jazan region of Saudi Arabia. Malays J Med Sci. 2013;20(2):41\u20136.","journal-title":"Malays J Med Sci"},{"issue":"6","key":"12432_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4103\/1319-3767.103425","volume":"18","author":"AA Abdo","year":"2012","unstructured":"Abdo AA, Sanai FM, Al-Faleh FZ. Epidemiology of viral hepatitis in Saudi arabia: are we off the hook? Saudi J Gastroenterol. 2012;18(6):349\u201357.","journal-title":"Saudi J Gastroenterol"},{"issue":"11","key":"12432_CR7","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.jiph.2020.09.004","volume":"13","author":"FM Sanai","year":"2020","unstructured":"Sanai FM, Alghamdi M, Dugan E, Alalwan A, Al-Hamoudi W, Abaalkhail F, et al. A tool to measure the economic impact of hepatitis B elimination: A case study in Saudi Arabia. J Infect Public Health. 2020;13(11):1715\u201323.","journal-title":"J Infect Public Health"},{"issue":"8","key":"12432_CR8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.15537\/smj.2018.8.22467","volume":"39","author":"I Altraif","year":"2018","unstructured":"Altraif I. Can hepatitis C virus be eliminated by 2030? Saudi Arabia as an example. Saudi Med J. 2018;39(8):842\u20135.","journal-title":"Saudi Med J"},{"issue":"2","key":"12432_CR9","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol"},{"issue":"2","key":"12432_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"JM Pawlotsky","year":"2018","unstructured":"Pawlotsky JM, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"key":"12432_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1186\/2193-1801-3-530","volume":"3","author":"A Abdul Salam","year":"2014","unstructured":"Abdul Salam A, Elsegaey I, Khraif R, Al-Mutairi A. Population distribution and household conditions in Saudi arabia: reflections from the 2010 census. SpringerPlus. 2014;3:530.","journal-title":"SpringerPlus"},{"issue":"3","key":"12432_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5144\/0256-4947.1993.231","volume":"13","author":"FZ Al-Faleh","year":"1993","unstructured":"Al-Faleh FZ, Ayoola EA, Al-Jeffry M, Arif M, Al-Rashed RS, Ramia S. Integration of hepatitis B vaccine into the expanded program on immunization: the Saudi Arabian experience. Ann Saudi Med. 1993;13(3):231\u20136.","journal-title":"Ann Saudi Med"},{"issue":"3","key":"12432_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5144\/0256-4947.2007.191","volume":"27","author":"TA Madani","year":"2007","unstructured":"Madani TA. Hepatitis C virus infections reported in Saudi Arabia over 11 years of surveillance. Ann Saudi Med. 2007;27(3):191\u20134.","journal-title":"Ann Saudi Med"},{"key":"12432_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2147\/HMER.S438099","volume":"15","author":"IG Alghamdi","year":"2023","unstructured":"Alghamdi IG, Alghamdi RM, Alghamdi MS, Alghamdi AM, Alghamdi MI, Alghamdi ZI, et al. Epidemiology of hepatitis B in Saudi Arabia from 2006 to 2021. Hepatic Med Evid Res. 2023;15:233\u201347.","journal-title":"Hepatic Med Evid Res"},{"issue":"2","key":"12432_CR15","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/j.ijid.2009.03.027","volume":"14","author":"ZA Memish","year":"2010","unstructured":"Memish ZA, Knawy BA, El-Saed A. Incidence trends of viral hepatitis A, B, and C seropositivity over eight years of surveillance in Saudi Arabia. Int J Infect Dis. 2010;14(2):e115\u2013120.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"12432_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/sjg.SJG_421_18","volume":"25","author":"AA Aljumah","year":"2019","unstructured":"Aljumah AA, Babatin M, Hashim A, Abaalkhail F, Bassil N, Safwat M, et al. Hepatitis B care pathway in Saudi arabia: current situation, gaps and actions. Saudi J Gastroenterol Off J Saudi Gastroenterol Assoc. 2019;25(2):73\u201380.","journal-title":"Saudi J Gastroenterol Off J Saudi Gastroenterol Assoc"},{"issue":"2","key":"12432_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","volume":"69","author":"S Schillie","year":"2020","unstructured":"Schillie S. CDC recommendations for hepatitis C screening among Adults \u2014 United States, 2020. MMWR Recomm Rep. 2020;69(2):1\u201317.","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"12432_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5694\/j.1326-5377.1992.tb137124.x","volume":"157","author":"GW McCaughan","year":"1992","unstructured":"McCaughan GW, McGuinness PH, Bishop GA, Painter DM, Lien AS, Tulloch R, et al. Clinical assessment and incidence of hepatitis C RNA in 50 consecutive RIBA-positive volunteer blood donors. Med J Aust. 1992;157(4):231\u20133.","journal-title":"Med J Aust"},{"key":"12432_CR19","unstructured":"Center for Global Health Equity. CGHE. [cited 2025 Aug 20]. Global Health Sector Strategy on Viral Hepatitis: 2016\u20132021 Towards Ending Viral Hepatitis. Available from: https:\/\/www.globalhep.org\/tools-resources\/action-plans\/global-health-sector-strategy-viral-hepatitis-2016-2021-towards-ending"},{"key":"12432_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.12688\/wellcomeopenres.17601.3","volume":"7","author":"R Brown","year":"2022","unstructured":"Brown R, Goulder P, Matthews PC. Sexual dimorphism in chronic hepatitis B virus (HBV) infection: evidence to inform elimination efforts. Wellcome Open Res. 2022;7:32.","journal-title":"Wellcome Open Res"},{"key":"12432_CR21","doi-asserted-by":"publisher","first-page":"e13828","DOI":"10.7717\/peerj.13828","volume":"10","author":"M Liu","year":"2022","unstructured":"Liu M, Li L, Zhao J, Ungvari GS, Ng CH, Duan Z, et al. Gender differences in demographic and clinical characteristics in patients with HBV-related liver diseases in China. PeerJ. 2022;10:e13828.","journal-title":"PeerJ"},{"key":"12432_CR22","unstructured":"Baig S. Gender disparity in infections of hepatitis B virus. J Coll Physicians Surg Pak. 2009 Sept;19(9):598\u2013600."},{"key":"12432_CR23","unstructured":"Hepatitis C-. Annual Epidemiological Report for 2022 [Internet]. 2024 [cited 2025 Aug 20]. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/hepatitis-c-annual-epidemiological-report-2022"},{"key":"12432_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1874357901710011001","volume":"11","author":"M Kolou","year":"2017","unstructured":"Kolou M, Katawa G, Salou M, Gozo-Akakpo KS, Dossim S, Kwarteng A, et al. High prevalence of hepatitis B virus infection in the age range of 20\u201339 years old individuals in Lome. Open Virol J. 2017;11:1\u20137.","journal-title":"Open Virol J"},{"issue":"1","key":"12432_CR25","first-page":"39","volume":"10","author":"A Esmaeelzadeh","year":"2017","unstructured":"Esmaeelzadeh A, Saadatnia H, Memar B, Mokhtari Amirmajdi E, Ganji A, Goshayeshi L, et al. Evaluation of serum HBV viral load, transaminases and histological features in chronic HBeAg-negative hepatitis B patients. Gastroenterol Hepatol Bed Bench. 2017;10(1):39\u201343.","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"12432_CR26","doi-asserted-by":"crossref","unstructured":"Hasanjani Roushan MR, Hajiahmadi M, Shafaie S. Histopathological features of liver and its relation to serum transaminase levels in 91 cases of anti-HBe-positive chronic hepatitis B. Int J Clin Pract. 2005 July;59(7):791\u20134.","DOI":"10.1111\/j.1742-1241.2005.00416.x"},{"key":"12432_CR27","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y, et al. Grazoprevir\u2013Elbasvir combination therapy for Treatment-Naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. Ann Intern Med. 2015 July;7(1):1\u201313.","DOI":"10.7326\/M15-0785"},{"issue":"8","key":"12432_CR28","first-page":"1516","volume":"91","author":"SE McCormick","year":"1996","unstructured":"McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol. 1996;91(8):1516\u201322.","journal-title":"Am J Gastroenterol"},{"key":"12432_CR29","doi-asserted-by":"crossref","unstructured":"Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet Lond Engl. 1993 June 12;341(8859):1501\u20134.","DOI":"10.1016\/0140-6736(93)90635-T"},{"issue":"2","key":"12432_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3329\/bmrcb.v34i2.1173","volume":"34","author":"FJ Rabbi","year":"2008","unstructured":"Rabbi FJ, Rezwan MK, Shirin T. HBeAg\/anti-HBe, Alanine aminotransferase and HBV DNA levels in HBsAg positive chronic carriers. Bangladesh Med Res Counc Bull. 2008;34(2):39\u201343.","journal-title":"Bangladesh Med Res Counc Bull"},{"issue":"4","key":"12432_CR31","first-page":"284","volume":"9","author":"KH Kim","year":"2003","unstructured":"Kim KH, Na IH, Cha JM, Cho YK, Park SY, Kim HP, et al. [Serum ALT and HBV DNA levels in patients with HBeAg-negative chronic hepatitis B]. Korean J Hepatol. 2003;9(4):284\u201392.","journal-title":"Korean J Hepatol"},{"issue":"4","key":"12432_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/jmv.1890390408","volume":"39","author":"KK Ljunggren","year":"1993","unstructured":"Ljunggren KK, Nordenfelt E, Kidd A. Correlation of HBeAg\/anti-HBe, ALT levels, and HBV DNA PCR results in HBsAg-positive patients. J Med Virol. 1993;39(4):297\u2013302.","journal-title":"J Med Virol"},{"key":"12432_CR33","doi-asserted-by":"crossref","unstructured":"Quirino A, Marascio N, Branda F, Ciccozzi A, Romano C, Locci C et al. Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies. Pathogens. 2024 Sept;13(9):766.","DOI":"10.3390\/pathogens13090766"},{"issue":"3","key":"12432_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nri1573","volume":"5","author":"B Rehermann","year":"2005","unstructured":"Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5(3):215\u201329.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"12432_CR35","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"N Terrault","year":"2018","unstructured":"Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M, et al. Update on Prevention, Diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatol Baltim Md. 2018;67(4):1560\u201399.","journal-title":"Hepatol Baltim Md"},{"key":"12432_CR36","doi-asserted-by":"crossref","unstructured":"Ijaz B, Ahmad W, Javed FT, Gull S, Sarwar MT, Kausar H et al. Association of laboratory parameters with viral factors in patients with hepatitis C. Virol J. 2011 July 21;8(1):361.","DOI":"10.1186\/1743-422X-8-361"},{"issue":"4","key":"12432_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.62940\/als.v8i4.1117","volume":"8","author":"S Amjad","year":"2021","unstructured":"Amjad S, Akram A, Iqbal M, Hussain M, Khan M. Analysis of ALT and AST levels in HCV infected patients. Adv Life Sci. 2021;8(4):349\u201354.","journal-title":"Adv Life Sci"},{"issue":"5","key":"12432_CR38","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/hep.510240505","volume":"24","author":"S Zeuzem","year":"1996","unstructured":"Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatol Baltim Md. 1996;24(5):1003\u20139.","journal-title":"Hepatol Baltim Md"},{"issue":"8","key":"12432_CR39","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","volume":"7","author":"CJ Alberts","year":"2022","unstructured":"Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJF, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022;7(8):724\u201335.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"12432_CR40","doi-asserted-by":"crossref","unstructured":"Babair Y, Elsafi S, Ghamdi MA, Gezery ME. Frequency and Pattern of Chronic Hepatitis B Infection in the Eastern Region of Saudi Arabia: A Cross-sectional Study. Biosci Biotechnol Res Asia [Internet]. 2016 May 7 [cited 2025 Aug 20];9(2). Available from: https:\/\/www.biotech-asia.org\/vol9no2\/frequency-and-pattern-of-chronic-hepatitis-b-infection-in-the-eastern-region-of-saudi-arabia-a-cross-sectional-study\/","DOI":"10.13005\/bbra\/1047"},{"issue":"1","key":"12432_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/sjhs.sjhs_197_19","volume":"9","author":"TA Sallam","year":"2020","unstructured":"Sallam TA, El-Bingawi HM, Alzahrani KI, Alzahrani BH, Alzahrani AA. Prevalence of hepatitis B and hepatitis C viral infections and impact of control program among blood donors in Al-Baha region, Saudi Arabia. Saudi J Health Sci. 2020;9(1):56.","journal-title":"Saudi J Health Sci"},{"key":"12432_CR42","doi-asserted-by":"crossref","unstructured":"El-Kassas M, Awad A. Metabolic aspects of hepatitis C virus. World J Gastroenterol. 2022 June;14(22):2429\u201336.","DOI":"10.3748\/wjg.v28.i22.2429"},{"key":"12432_CR43","doi-asserted-by":"crossref","unstructured":"Asaad AM, Al-Ayed MSZ, Aleraky M, Qureshi MA. Hepatitis B virus genotyping in chronic hepatitis B patients in southwestern Saudi Arabia. Braz J Infect Dis. 2015 Sept 1;19(5):525\u20138.","DOI":"10.1016\/j.bjid.2015.03.007"},{"issue":"3","key":"12432_CR44","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/hep.30303","volume":"69","author":"H Park","year":"2019","unstructured":"Park H, Wang W, Henry L, Nelson DR. Impact of All-Oral Direct\u2010Acting antivirals on clinical and economic outcomes in patients with chronic hepatitis C in the united States. Hepatology. 2019;69(3):1032\u201340.","journal-title":"Hepatology"},{"issue":"11\u201312","key":"12432_CR45","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1111\/apt.18278","volume":"60","author":"M Buti","year":"2024","unstructured":"Buti M, Lim Y, Chan HLY, Agarwal K, Marcellin P, Brunetto MR, et al. Eight-year efficacy and safety of Tenofovir Alafenamide for treatment of chronic hepatitis B virus infection: final results from two randomised phase 3 trials. Aliment Pharmacol Ther. 2024;60(11\u201312):1573\u201386.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"12432_CR46","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, et al. Long-Term treatment with Tenofovir Alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2024;119(3):486\u201396.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"12432_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1665-2681(19)30861-0","volume":"13","author":"E Ridruejo","year":"2014","unstructured":"Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Mu\u00f1oz AE, Adrover R, et al. Efficacy and safety of long term Entecavir in chronic hepatitis B treatment na\u00efve patients in clinical practice. Ann Hepatol. 2014;13(3):327\u201336.","journal-title":"Ann Hepatol"},{"key":"12432_CR48","doi-asserted-by":"crossref","unstructured":"Lee HW, Kwon JC, Oh IS, Chang HY, Cha YJ, Choi IS, et al. Prolonged Entecavir therapy is not effective for hbeag seroconversion in Treatment-Naive chronic hepatitis B patients with a partial virological response. Antimicrob Agents Chemother. 2015 Sept;59(9):5348\u201356.","DOI":"10.1128\/AAC.01017-15"},{"issue":"11","key":"12432_CR49","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.3748\/wjg.v20.i11.2876","volume":"20","author":"N Toshikuni","year":"2014","unstructured":"Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol WJG. 2014;20(11):2876\u201387.","journal-title":"World J Gastroenterol WJG"},{"issue":"3","key":"12432_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus Sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321.","journal-title":"N Engl J Med"},{"key":"12432_CR51","doi-asserted-by":"crossref","unstructured":"Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NNH. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Hepatol Int. 2018 July;12(4):339\u201347.","DOI":"10.1007\/s12072-018-9861-2"},{"key":"12432_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/IDR.S160593","volume":"11","author":"OA Ahmed","year":"2018","unstructured":"Ahmed OA, Elsebaey MA, Fouad MHA, Elashry H, Elshafie AI, Elhadidy AA, et al. Outcomes and predictors of treatment response with Sofosbuvir plus Daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection. Infect Drug Resist. 2018;11:441\u20135.","journal-title":"Infect Drug Resist"},{"key":"12432_CR53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12985-024-02544-2","volume":"21","author":"AN Farrag","year":"2024","unstructured":"Farrag AN, Kamel AM. Efficacy of 8-week daclatasvir-sofosbuvir regimen in chronic hepatitis C: a systematic review and meta-analysis. Virol J. 2024;21:275.","journal-title":"Virol J"},{"issue":"2","key":"12432_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"M Puoti","year":"2018","unstructured":"Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, et al. High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis. J Hepatol. 2018;69(2):293\u2013300.","journal-title":"J Hepatol"},{"issue":"2","key":"12432_CR55","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and Pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis. J Hepatol. 2017;67(2):263\u201371.","journal-title":"J Hepatol"},{"issue":"5","key":"12432_CR56","doi-asserted-by":"publisher","first-page":"323","DOI":"10.20344\/amp.19178","volume":"37","author":"J Vera","year":"2024","unstructured":"Vera J, Gomes A, P\u00f3voas D, Seixas D, Maltez F, Pedroto I, et al. Real-World effectiveness and safety of Glecaprevir\/Pibrentasvir for the treatment of chronic hepatitis C: A prospective cohort study in Portugal. Acta M\u00e9dica Port. 2024;37(5):323\u201333.","journal-title":"Acta M\u00e9dica Port"},{"key":"12432_CR57","doi-asserted-by":"crossref","unstructured":"Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, et al. Efficacy of Elbasvir and Grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. Liver Int Off J Int Assoc Study Liver. 2018 Sept;38(9):1583\u201391.","DOI":"10.1111\/liv.13727"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12432-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:02:14Z","timestamp":1768507334000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12432-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12432"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12432-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7767890\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the Declaration of Helsinki the study protocol was approved by the Ethics Research Committee (ERC) of the Faculty of Medicine, Al-Baha University (Ethical approval number: REC\/MIC\/\/BU-FM\/2022\/63R). Data was obtained on written consent to the King Fahd Hospital, and no consent was required from participants as the study is retrospective.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This manuscript does not contain any individual person\u2019s data in any form either individual details, images or videos.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}